PTGX — Protagonist Therapeutics Inc. stock price and chart

Share this page

PTGX

$128.75-5.71%

as of close, Oct 16, 2026

☾ AH $128.75 -5.71%

Protagonist Therapeutics Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.01%US Stock Market 0.01%Russell 3000 0.010%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

20.040.060.080.0100.0120.0140.0020.0M40.0M$128.75

2026-10-16

Price$128.75

MA20$129.88

MA50$101.27

Vol5.0M

What would $1,000 invested in PTGX be worth today? →

PTGX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $128.75
YTD price return: +47.41%
YTD total return: +47.41%
Next earnings: Nov 5, 2026
Market cap: 8.3B2016-12 367.6M2026-10 8.3B+2167.2% over the window
Enterprise value: 7.6B
Shares outstanding: 64.7M2016-06 16.5M2026-06 64.7M+293.1% over the window
52W low: $73.08
52W high: $160.81
From 52W high: -19.94%
From 52W low: +76.18%
52W range: 63%

Volume

Rel volume: 1.13×
30D volume: 783.7K
30D $ vol: 110.8M

Fundamentals

Sales (ttm): 74.1M2017-12 20.1M2026-03 74.1M+269.2% over the window
Sales/share: $1.142017-12 $0.952026-03 $1.15+21.1% over the window
EPS (ttm): $1.232020-12 -$1.922026-06 $1.23-164.1% over the window
FCF (ttm): 130.6M2016-06 -22.4M2026-06 130.6M-682.1% over the window
FCF/share: $2.022016-06 -$1.362026-06 $2.02-248.1% over the window
Book value/share: $13.012016-06 -$2.812026-06 $13.01-563.3% over the window
Net margin: 111.94%2017-12 -184.2%2026-03 -154.9%-15.9% over the window
ROE: 9.85%2016-09 -32.2%2026-06 9.9%-130.6% over the window
ROA: 9.36%2016-06 -113.3%2026-06 9.4%-108.3% over the window
Current ratio: 21.712016-06 5.452026-06 21.71+298.0% over the window

Growth (CAGR, ttm) · 10Y

Sales: -64.38%2025-03-31 → 2026-03-31207.8M → 74.1M (-64.4% total)+341.63%2023-03-31 → 2026-03-31859K → 74.1M (+8522.0% total)+19.87%2020-12-31 → 2026-03-3128.6M → 74.1M (+158.7% total)n/a
Net income: +59.37%2025-06-30 → 2026-06-3052M → 82.9M (+59.3% total)n/an/an/a
FCF: +252.29%2025-06-30 → 2026-06-3037.1M → 130.6M (+252.0% total)n/an/an/a
Shares: +4.02%2025-06-30 → 2026-06-3062.2M → 64.7M (+4.0% total)+4.00%2023-06-30 → 2026-06-3057.5M → 64.7M (+12.5% total)+6.36%2021-06-30 → 2026-06-3047.6M → 64.7M (+36.1% total)+14.67%2016-06-30 → 2026-06-3016.5M → 64.7M (+293.1% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +50.73%2025-06-30 → 2026-06-30$0.82 → $1.23 (+50.7% total)n/an/an/a
Sales/share: -65.67%2025-03-31 → 2026-03-31$3.35 → $1.15 (-65.6% total)+324.84%2023-03-31 → 2026-03-31$0.02 → $1.15 (+7575.5% total)+11.41%2020-12-31 → 2026-03-31$0.65 → $1.15 (+76.2% total)n/a
FCF/share: +238.68%2025-06-30 → 2026-06-30$0.60 → $2.02 (+238.4% total)n/an/an/a
Book value/share: +21.13%2025-06-30 → 2026-06-30$10.74 → $13.01 (+21.1% total)+36.51%2023-06-30 → 2026-06-30$5.11 → $13.01 (+154.4% total)+11.59%2021-06-30 → 2026-06-30$7.52 → $13.01 (+73.0% total)n/a
Price: +70.07%2025-10-16 → 2026-10-16$75.73 → $128.75 (+70.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+101.28%2023-10-16 → 2026-10-16$15.78 → $128.75 (+715.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+32.96%2021-10-15 → 2026-10-16$30.97 → $128.75 (+315.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+19.61%2016-10-14 → 2026-10-16$21.46 → $128.75 (+500.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +70.07%2025-10-16 → 2026-10-16$75.73 → $128.75 (+70.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+101.28%2023-10-16 → 2026-10-16$15.78 → $128.75 (+715.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+32.96%2021-10-15 → 2026-10-16$30.97 → $128.75 (+315.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+19.61%2016-10-14 → 2026-10-16$21.46 → $128.75 (+500.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 104.6×2016-12 -11.702026-10 100.51-959.3% over the window
Fwd P/E: -721.7×
P/S (ttm)Market cap ÷ TTM revenue.: 112.5×2018-03 9.042026-10 112.51+1145.2% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 9.9×2016-12 3.772026-10 9.90+162.7% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 63.8×2016-12 -14.392026-10 63.82-543.5% over the window
EV/EBITDA (fy): 126.2×
EV/Sales (ttm): 102.1×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 1.57%2016-09 -7.0%2026-06 1.6%-123.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 64.7M ÷ 62.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -4.02%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-4.02%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($3.4B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -4.02%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($8.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-09 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($8.3B). Same caveat as the cash buyback yield.: 0.00%2016-09 0.0%2026-06 0.0%

Vs own 10Y history

P/S: 79th
P/B: 95th

Bar = where today’s multiple sits in PTGX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-5.71%

-10.42%

-9.86%

-2.48%

YTD

+47.41%

+70.01%

+315.72%

Financial statements

Open full PTGX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

PTGX — Protagonist Therapeutics Inc. price, chart and key statistics